engineered an oncolytic herpes simplex virus vector expressing a human PD-1 single-chain variable fragment (hPD-1scFv), termed YST-OVH, which substantially amplified the activity of CD8+ T cells within mouse tumors and demonstrated significant antitumor effects across various humanized PD-1 mouse tumor models (30). The gene discussed is CD8A; the disease is neoplasm.